Adding Revlimid to RCHOP21 Looks Good in Elderly DLBCL Patients

An open-label phase II study demonstrates the safety and efficacy of adding lenalidomide to RCHOP21 for elderly patients with treatment naïve diffuse large B-cell lymphoma (DLBCL).

According to Umberto Vitolo MD of Azienda Ospedaliera Citta della Salute e della Scienza di Torino in Italy and colleagues, as many as 40 percent of this patient population that receives RCHOP21 (the RCHOP regimen delivered on a 21 day cycle) will relapse or develop refractory disease.

Since lenalidomide (brand name: Revlimid) is known to be active against relapsed or refractory B-cell lymphomas, Vitolo and his colleagues decided to see if it would help response rates among this population.

They recruited 49 patients aged 69 to 80 with newly diagnosed and untreated CD20 positive stage II-IV DLBCL or grade 3b follicular lymphoma.

Patients were given 15 mg oral lenalidomide on days 1 through 14 of the 21 day cycle for a total of six cycles, coupled with standard doses of RCHOP21.

Their findings indicated that 45 of 49 patients, or 91.8 percent, achieved some response, while 42 patients achieved a complete response and the other three, a partial response. One patient died of causes unrelated to lymphoma or treatment.

Furthermore, patients appeared able to tolerate the treatment, with 94 percent of planned treatment cycles completed.

Adverse events included grade 3 or 4 neutropenia, leukopenia, and thrombocytopenia.

Source: Healio

More Articles

More Articles

In T cell lymphoma, T lymphocytes, which are an essential part of the body's immune response, become malignant. T cell lymphomas account for about...

Lymphomatoid Papulosis (LyP) is a rare skin disorder that involves cancerous looking skin lesions. It is more than a skin condition; it is the...

In non-Hodgkin's lymphoma, you have your B-cell lymphomas and you have your T-cell lymphomas.

Why B...

MALT lymphoma is a rare B-cell non-Hodgkin's lymphoma that typically runs an indolent or slow-growing clinical...

Mantle cell lymphoma (MCL) is a relatively rare B-cell subtype of non-Hodgkin'...

T-Cell Lymphoblastic Lymphoma (T-LBL) is a very rare subtype of non-Hodgkin's lymphoma. It tends to develop in...

In general, a diagnosis of T-cell lymphoma denotes a poorer prognosis than a diagnosis of B-cell lymphoma. One of...

Mantle cell lymphoma (MCL) is just one of 50-60 known B-cell subtypes of...

After some of the dust has settled, the thoughts of many new lymphoma patients turn to diet and nutrition. They want to know if, in the past,...

The term NK T cell lymphoma refers to one of two subtypes of lymphoma that affect the NK (Natural Killer)...

In a perfect world, every case of cancer would respond to, and be cured by first-line therapy. Unfortunately, it is not often the case. This is...

Prednisone is a glucocorticosteroid (a steroid) used in the treatment of many types of cancers. It functions as an anti-inflammatory medicine that...

In 1964, researchers at the National Cancer Institute developed the first combination chemotherapy that cured a...